Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model
Authors: Lu Simeng , Yin Zhenzhen , Wu Limeng , Sun Yao , Chen Jie , Wu Lai Man Natalie , Oblinger Janet L. , Blake Day Caven , Landegger Lukas D. , Seist Richard , Ho William , Xiu Bingyu , Jones Adam P. , Muzikansky Alona , Stankovic Konstantina M. , Plotkin Scott R. , Chang Long-Sheng , Xu Lei 
Published: December 2024

Background

NF2-related schwannomatosis (NF2-SWN) is a debilitating condition that calls for robust treatment options. The defining feature ofNF2-SWN is the presence of bilateral vestibular schwannomas (VSs), which grow over time and can result in irreversible sensorineural hearing loss, significantly affecting the quality of life for those affected. At present, there are no FDA-approved medications specifically for treating VS or related hearing loss. VS management involves radiotherapy or surgical resection, while bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody (αVEGF) may be used off-label inNF2-SWN to shrink the tumor. However, not all patients respond, and the effect is not always durable. There is a critical need for effective medications that can stop the growth of VS and prevent hearing loss associated with these tumors. While immune checkpoint inhibitors have transformed cancer therapy, their potential has not been thoroughly explored in non-malignant tumors such as VS.

Methods

We characterize the effects of anti-PD1 (αPD1) treatment on tumor growth and hearing function in two syngeneic, immune-competent VS models.

Results

We demonstrated that combining αVEGF treatment with αPD1 significantly enhances the efficacy of each monotherapy. Specifically, i) αVEGF enhances αPD1 efficacy by normalizing the tumor vasculature to improve drug delivery and immune cell infiltration, and by activating T cell and NK cell anti-tumor cytotoxicity via NKG2D upregulation; and ii) combining αPD1 with αVEGF treatment effectively controls tumors that progressed despite αVEGF treatment.

Conclusion

These findings provide a strong foundation for the development of αPD1 with αVEGF combination therapies for patients withNF2-SWN.

Key points

We filled a critical gap in NF2 research:

1) we characterized the effects of immunotherapy on tumor growth and hearing function in non-malignant vestibular schwannomas

2) We showed combined anti-VEGF and anti-PD1 enhances the efficacy of each monotherapy

Importance of the study

Treatment options for patients withNF2-SWN are limited or are associated with significant co-morbidities. There are no approved medical treatments for NF2-related tumors. While immune checkpoint inhibitors have transformed cancer therapy, their potential has not been thoroughly explored in non-malignant tumors such as VS. Our work filled this critical gap inNF2-SWN research. For the first time, we systemically evaluated ICI efficacy on tumor growth and hearing function in non-malignant schwannomas.

Furthermore, we demonstrated that combining αVEGF treatment with αPD1 significantly enhances the efficacy of each monotherapy. Specifically: i) αVEGF enhances αPD1 efficacy by normalizing the tumor vasculature to improve drug delivery and immune cell infiltration, and by activating T cell and NK cell anti-tumor cytotoxicity via NKG2D upregulation; and ii) combining αPD1 with αVEGF treatment effectively controls tumors that progress despite αVEGF treatment.

Our findings provide a strong foundation for the development of αPD1 with αVEGF combination therapies for patients withNF2-SWN.